$ABCL
AbCellera Biologics Inc. Stock $abcl

$abcl Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024035248 Filed on August 06, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$6.507M	$7.323M
YoY Change	-1.39%	-27.18%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$22.28M	$23.33M
YoY Change	24.92%	20.48%
% of Gross Profit
Research & Development	$40.97M	$40.93M
YoY Change	8.05%	12.21%
% of Gross Profit
Depreciation & Amortization	$3.800M	$3.400M
YoY Change	22.58%	-39.39%
% of Gross Profit
Operating Expenses	$100.2M	$100.8M
YoY Change	62.91%	64.01%
Operating Profit	-$93.66M	-$93.45M
YoY Change	70.64%	81.86%
Interest Expense	$9.603M	$9.801M
YoY Change	-10.25%	-9.07%
% of Operating Profit
Other Income/Expense, Net	$31.03M	$45.27M
YoY Change	98.74%	1637.03%
Pretax Income	-$62.63M	-$48.19M
YoY Change	59.47%	26.79%
Income Tax	-$11.53M	-$11.26M
% Of Pretax Income
Net Earnings	-$51.11M	-$36.93M
YoY Change	78.63%	20.97%
Net Earnings / Revenue	-785.42%	-504.3%
Basic Earnings Per Share	-$0.17	-$0.13
Diluted Earnings Per Share	-$0.17	-$0.13
COMMON SHARES
Basic Shares Outstanding	294.7M shares	294.1M shares
Diluted Shares Outstanding	294.9M shares	294.2M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$643.1M	$670.4M
YoY Change	-18.15%	272.94%
Cash & Equivalents	$126.6M	$148.3M
Short-Term Investments	$516.5M	$522.0M
Other Short-Term Assets	$43.37M	$40.06M
YoY Change	-39.11%	-15.43%
Inventory
Prepaid Expenses
Receivables	$31.37M	$36.14M
Other Receivables	$31.86M	$31.56M
Total Short-Term Assets	$742.9M	$771.6M
YoY Change	-19.21%	-17.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$331.3M	$318.9M
YoY Change	19.5%	22.82%
Goodwill	$47.81M	$47.81M
YoY Change	0.0%	0.0%
Intangibles	$52.58M	$85.66M
YoY Change	-57.63%	-32.42%
Long-Term Investments	$84.08M	$76.06M
YoY Change	33.68%	29.38%
Other Assets	$134.2M	$112.5M
YoY Change	66.33%	-0.82%
Total Long-Term Assets	$649.9M	$640.9M
YoY Change	9.66%	5.69%
TOTAL ASSETS
Total Short-Term Assets	$742.9M	$771.6M
Total Long-Term Assets	$649.9M	$640.9M
Total Assets	$1.393B	$1.412B
YoY Change	-7.89%	-8.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$34.80M	$26.59M
YoY Change	99.97%	26.44%
Accrued Expenses	$11.12M	$9.960M
YoY Change	-6.58%	67.31%
Deferred Revenue	$5.578M	$6.401M
YoY Change	-68.14%	-25.06%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$79.57M	$70.38M
YoY Change	-27.82%	-40.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.524M	$6.348M
YoY Change	-69.83%	-96.66%
Total Long-Term Liabilities	$235.2M	$231.1M
YoY Change	7.3%	21.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$79.57M	$70.38M
Total Long-Term Liabilities	$235.2M	$231.1M
Total Liabilities	$314.7M	$301.5M
YoY Change	-4.46%	-11.93%
SHAREHOLDERS EQUITY
Retained Earnings	$151.1M	$202.2M
YoY Change	-53.77%	-43.12%
Common Stock	$928.2M	$910.8M
YoY Change	8.27%	8.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.078B	$1.111B
YoY Change
Total Liabilities & Shareholders Equity	$1.393B	$1.412B
YoY Change	-7.89%	-8.11%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$51.11M	-$36.93M
YoY Change	78.63%	20.97%
Depreciation, Depletion And Amortization	$3.800M	$3.400M
YoY Change	22.58%	-39.39%
Cash From Operating Activities	-$28.88M	-$29.97M
YoY Change	28782.0%	-250.56%
INVESTING ACTIVITIES
Capital Expenditures	$18.52M	$20.11M
YoY Change	-11.41%	-26.07%
Acquisitions
YoY Change
Other Investing Activities	$22.21M	$72.21M
YoY Change	174.25%	-1104.42%
Cash From Investing Activities	$3.698M	$52.10M
YoY Change	-128.89%	-251.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.145M	2.651M
YoY Change	-52.35%	532.7%
NET CHANGE
Cash From Operating Activities	-28.88M	-29.97M
Cash From Investing Activities	3.698M	52.10M
Cash From Financing Activities	3.145M	2.651M
Net Change In Cash	-22.04M	24.78M
YoY Change	249.83%	-276.17%
FREE CASH FLOW
Cash From Operating Activities	-$28.88M	-$29.97M
Capital Expenditures	$18.52M	$20.11M
Free Cash Flow	-$47.40M	-$50.08M
YoY Change	125.7%	586.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	294217013	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	288357081	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.abcellera.com/20240630#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.abcellera.com/20240630#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization
CY2024Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1233277000	usd
CY2023Q1	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	489000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15474000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-630000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40110000	usd
	us-gaap	Profit Loss ProfitLoss	-70638000	usd
	us-gaap	Profit Loss ProfitLoss	-77540000	usd
	us-gaap	Depreciation Depreciation	5810000	usd
	us-gaap	Depreciation Depreciation	6603000	usd
	abcl	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	5314000	usd
	abcl	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	34763000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3252000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3437000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	31873000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	35191000	usd
	abcl	Gain On Contingent Consideration GainOnContingentConsideration	0	usd
	abcl	Gain On Contingent Consideration GainOnContingentConsideration	30920000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	4429000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	8193000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	24269000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	34434000	usd
	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	-9260000	usd
	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	0	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	22884000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-5953000	usd
	abcl	Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable	-2827000	usd
	abcl	Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable	-130000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4870000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12782000	usd
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-16253000	usd
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	0	usd
	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-25566000	usd
	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-19757000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4833000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1473000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24160000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-71674000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42185000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44250000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	528891000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	426007000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	422814000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	539385000	usd
	abcl	Proceeds From Receipt Of Grant Funding ProceedsFromReceiptOfGrantFunding	7693000	usd
	abcl	Proceeds From Receipt Of Grant Funding ProceedsFromReceiptOfGrantFunding	19750000	usd
	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	36757000	usd
	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	-3950000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	6673000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	10820000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-183999000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	82008000	usd
	abcl	Payments Of Liability For In Licensing Agreement And Other PaymentsOfLiabilityForInLicensingAgreementAndOther	863000	usd
	abcl	Payments Of Liability For In Licensing Agreement And Other PaymentsOfLiabilityForInLicensingAgreementAndOther	368000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	4497000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	824000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1353000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-39000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5482000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	584000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-824000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-207614000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14992000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	414651000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	160610000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	207037000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	175602000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2290000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2290000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	204747000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	173312000	usd
	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	11718000	usd
	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	15944000	usd
	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	2945000	usd
	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	452000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of operations<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbCellera Biologics Inc.’s (the “Company”) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs and to develop its own pipeline of future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div>The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, the impairment assessment of intangible assets and goodwill, and contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30528000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-30528000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-36930000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36930000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-70638000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-70638000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-77540000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-77540000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	288905587	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	288905587	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	294217013	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	288357081	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	293467753	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	293467753	shares
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50707389	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50775907	shares
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	58545821	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	58804118	shares
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	73141000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	70156000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsBeforeAccumulatedDepreciationAndAmortization	318304000	usd
CY2024Q2	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsBeforeAccumulatedDepreciationAndAmortization	354991000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAccumulatedDepreciationAndAmortization	30608000	usd
CY2024Q2	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAccumulatedDepreciationAndAmortization	36109000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization	287696000	usd
CY2024Q2	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization	318882000	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	91000000.0	usd
CY2024Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	108200000	usd
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	13700000	usd
CY2024Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	13000000.0	usd
CY2023Q2	us-gaap	Depreciation Depreciation	3000000.0	usd
	us-gaap	Depreciation Depreciation	5800000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	3400000	usd
	us-gaap	Depreciation Depreciation	6600000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	123143000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	37482000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	85661000	usd
CY2024Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	32000000	usd
CY2024Q2	abcl	Impairment Of Intangible Assets Finite Lived Net Of Deferred Income Tax ImpairmentOfIntangibleAssetsFiniteLivedNetOfDeferredIncomeTax	23200000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	4297000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	4297000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	4297000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	4297000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	4297000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21485000	usd
	abcl	Number Of Joint Ventures NumberOfJointVentures	2	jointventure
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	33792000	usd
CY2024Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	31560000	usd
CY2023Q4	abcl	Prepaid Expense And Other Current PrepaidExpenseAndOtherCurrent	22018000	usd
CY2024Q2	abcl	Prepaid Expense And Other Current PrepaidExpenseAndOtherCurrent	8495000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	55810000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	40055000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	28603000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	26585000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6158000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5603000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7707000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4357000	usd
CY2023Q4	abcl	Deferred Grant Funding Current DeferredGrantFundingCurrent	7112000	usd
CY2024Q2	abcl	Deferred Grant Funding Current DeferredGrantFundingCurrent	7407000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	49580000	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	43952000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16399000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17782000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31873000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35191000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	41128000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	36258000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	27153000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	14371000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4000000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	8100000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4400000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	13000000	usd
CY2024Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	32300000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	32300000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P0Y7M6D
CY2023Q2	us-gaap	Royalty Expense RoyaltyExpense	0	usd
	us-gaap	Royalty Expense RoyaltyExpense	0	usd
	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2024Q2	us-gaap	Royalty Expense RoyaltyExpense	0	usd
	abcl	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	Government Contribution 1
CY2024Q2	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	44449000	usd
CY2024Q2	us-gaap	Government Assistance Liability GovernmentAssistanceLiability	131593000	usd
CY2023Q4	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	36051000	usd
CY2023Q4	us-gaap	Government Assistance Liability GovernmentAssistanceLiability	103027000	usd
CY2024Q2	us-gaap	Government Assistance Amount Cumulative Current GovernmentAssistanceAmountCumulativeCurrent	31632000	usd
CY2024Q2	us-gaap	Government Assistance Liability Current GovernmentAssistanceLiabilityCurrent	7407000	usd
CY2024Q2	us-gaap	Government Assistance Amount Cumulative Noncurrent GovernmentAssistanceAmountCumulativeNoncurrent	12817000	usd
CY2024Q2	us-gaap	Government Assistance Liability Noncurrent GovernmentAssistanceLiabilityNoncurrent	124186000	usd
	us-gaap	Government Assistance Transaction Duration GovernmentAssistanceTransactionDuration	P8Y
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-035248-index-headers.html	Edgar Link	pending
0001628280-24-035248-index.html	Edgar Link	pending
0001628280-24-035248.txt	Edgar Link	pending
0001628280-24-035248-xbrl.zip	Edgar Link	pending
a2020shareoptionandincen.htm	Edgar Link	pending
a2020shareoptionandincen001.jpg	Edgar Link	pending
a2020shareoptionandincen002.jpg	Edgar Link	pending
abcl-20240630_lab.xml	Edgar Link	unprocessable
a2020shareoptionandincen003.jpg	Edgar Link	pending
a2020shareoptionandincen004.jpg	Edgar Link	pending
a2020shareoptionandincen005.jpg	Edgar Link	pending
a2020shareoptionandincen006.jpg	Edgar Link	pending
a2020shareoptionandincen007.jpg	Edgar Link	pending
a2020shareoptionandincen008.jpg	Edgar Link	pending
a2020shareoptionandincen009.jpg	Edgar Link	pending
a2020shareoptionandincen010.jpg	Edgar Link	pending
a2020shareoptionandincen011.jpg	Edgar Link	pending
a2020shareoptionandincen012.jpg	Edgar Link	pending
a2020shareoptionandincen013.jpg	Edgar Link	pending
a2020shareoptionandincen014.jpg	Edgar Link	pending
a2020shareoptionandincen015.jpg	Edgar Link	pending
a2020shareoptionandincen016.jpg	Edgar Link	pending
a2020shareoptionandincen017.jpg	Edgar Link	pending
a2020shareoptionandincen018.jpg	Edgar Link	pending
a2020shareoptionandincen019.jpg	Edgar Link	pending
abcl-20240630.htm	Edgar Link	pending
abcl-20240630.xsd	Edgar Link	pending
abcl-20240630xexx311.htm	Edgar Link	pending
abcl-20240630xexx312.htm	Edgar Link	pending
abcl-20240630xexx321.htm	Edgar Link	pending
abcl-20240630xexx322.htm	Edgar Link	pending
abcl-20240630_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
abcl-20240630_def.xml	Edgar Link	unprocessable
abcl-20240630_pre.xml	Edgar Link	unprocessable
abcl-20240630_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
seventhamendedandrestate.htm	Edgar Link	pending
seventhamendedandrestate001.jpg	Edgar Link	pending
seventhamendedandrestate002.jpg	Edgar Link	pending
seventhamendedandrestate003.jpg	Edgar Link	pending
seventhamendedandrestate004.jpg	Edgar Link	pending
seventhamendedandrestate005.jpg	Edgar Link	pending
seventhamendedandrestate006.jpg	Edgar Link	pending
seventhamendedandrestate007.jpg	Edgar Link	pending
seventhamendedandrestate008.jpg	Edgar Link	pending
seventhamendedandrestate009.jpg	Edgar Link	pending
seventhamendedandrestate010.jpg	Edgar Link	pending
seventhamendedandrestate011.jpg	Edgar Link	pending
seventhamendedandrestate012.jpg	Edgar Link	pending
seventhamendedandrestate013.jpg	Edgar Link	pending
seventhamendedandrestate014.jpg	Edgar Link	pending
seventhamendedandrestate015.jpg	Edgar Link	pending
seventhamendedandrestate016.jpg	Edgar Link	pending
seventhamendedandrestate017.jpg	Edgar Link	pending
seventhamendedandrestate018.jpg	Edgar Link	pending
seventhamendedandrestate019.jpg	Edgar Link	pending
seventhamendedandrestate020.jpg	Edgar Link	pending
seventhamendedandrestate021.jpg	Edgar Link	pending
seventhamendedandrestate022.jpg	Edgar Link	pending
seventhamendedandrestate023.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
abcl-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABCL
AbCellera Biologics Inc. Stock $abcl

2024 Q3 Form 10-Q Financial Statement

#000162828024035248 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABCL AbCellera Biologics Inc. Stock $abcl

2024 Q3 Form 10-Q Financial Statement

#000162828024035248 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABCL
AbCellera Biologics Inc. Stock $abcl